Sun Pharma inks pact with LIB Therapeutics to sell LDL-C drug

Sun Pharmaceutical Industries and LIB Therapeutics Inc on Monday announced an exclusive licensing agreement granting the Indian drug maker rights to commercialise and manufacture lerodalcibep worldwide, excluding the U.S. and China.

The agreement establishes a new growth platform for it in a large and rapidly expanding market, Sun Pharma said.

IQVIA numbers show the PCSK9 inhibitor market outside the U.S. and China reached $ 3.7 billion in the period ending Q2 2026 (MAT Q2 2026), showing a 38% CAGR (compounded annual growth rate) over the preceding two years. Europe alone accounted for $ 2.9 billion PCSK9 inhibitor market in MAT Q2 2026, Sun Pharma said.